NCT06427538 Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas
| NCT ID | NCT06427538 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Empyema, Pleural |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2024-06-21 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2024-06-21 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Infections of the pleural space are common, and patients require antibiotics and chest drain placement to evacuate the chest from the infected fluid. Chest drains can get blocked by the drainage fluid and material. For this reason, it is thought that flushing the chest drain with saline solution, can help maintain the patency of the tube. This proposed study will evaluate the impact of regular chest drain flushing on the length of time to chest tube removal and total hospitalization as well as improvement in chest imaging and the need for additional interventions on the infected space.
Eligibility Criteria
Inclusion Criteria: * Patients with complicated parapneumonic pleural effusion and empyema requiring chest tube placement as standard of care for inpatient management of their pleural space infection with or without intrapleural tissue plasminogen activator and deoxyribonuclease therapy * Age \> 18 years old. Exclusion Criteria: * Patients who have surgical tubes that can't accommodate a three-way stopcock. * Study subject has any disease or condition that interferes with the safe completion of the study. * Inability to provide informed consent. * Inability to undergo a chest X-ray. * If the managing clinician believes the chest tube will be placed for less than 24 hours. * Patients with an indwelling pleural catheter (IPC)
Contact & Investigator
Jennifer D Duke, MD
STUDY DIRECTOR
Vanderbilt University
Frequently Asked Questions
Who can join the NCT06427538 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Empyema, Pleural. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06427538 currently recruiting?
Yes, NCT06427538 is actively recruiting participants. Contact the research team at samira.shojaee@vumc.org for enrollment information.
Where is the NCT06427538 trial being conducted?
This trial is being conducted at Sterling Heights, United States, Omaha, United States, New York, United States, Nashville, United States and 1 additional location.
Who is sponsoring the NCT06427538 clinical trial?
NCT06427538 is sponsored by Vanderbilt University Medical Center. The principal investigator is Jennifer D Duke, MD at Vanderbilt University. The trial plans to enroll 96 participants.